TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

NCT ID: NCT03720431

Last Updated: 2022-08-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 11 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-01-03
• Study Completion Date: 2022-10-26

Brief Summary

This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.

Conditions

Triple Negative Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TTAC-0001 and pembrolizumab

TTAC-0001 and pembrolizumab combination therapy will be administered.

Group Type: EXPERIMENTAL

TTAC-0001 and pembrolizumab combination

Intervention Type: DRUG

• Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)
• Treatment groups: 3 dose levels

• Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
• Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
• Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
• Cycle: 3 weeks (21 days per cycle)

Interventions

TTAC-0001 and pembrolizumab combination

• Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)
• Treatment groups: 3 dose levels

• Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
• Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
• Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
• Cycle: 3 weeks (21 days per cycle)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Female and male patients ≥18 years old

2. Histologically proven metastatic breast carcinoma with triple negative receptor status (Estrogen receptor, Progesterone receptor and human epidermal growth factor receptor 2 [HER2] negative) by IHC and Fluorescence in situ hybridization (FISH) according to ASCO-CAP guideline3.

3. At least one confirmed measurable lesion by RECIST 1.1 criteria

4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

5. A person who satisfies the following criteria in hematologic, renal, and hepatic function tests performed within 7 days prior to screening:

(1) Hematologic tests

• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
• Platelets ≥ 100 x 109/L
• Haemoglobin ≥ 9.0 g/dL (2) Blood coagulation tests
• Prothrombin time (PT) ≤ 1.5 x Upper limit of normal (UNL)
• Activated partial thromboplastin Time (aPTT) ≤ 1.5 x UNL (3) Hepatic function tests
• Total bilirubin ≤ 1.5 x UNL
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metastasis) (4) Renal function test
• ≤1.5 × ULN or creatinine clearance (CrCl) ≥30 mL/min for patient with creatinine levels >1.5 × institutional ULN 6) At least 12 weeks of expected life expectancy 7) The patient (or legally acceptable representative if applicable) is able and willing to provide written informed consent for the trial.

Exclusion Criteria

1. Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. (Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) controlled by curative therapy are not excluded)

2. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment

3. Has a history of (non-infectious) pneumonitis/interstitial lung diseases that required steroids or current pneumonitis/interstitial lung disease.

4. Has an active infection requiring systemic therapy

5. Uncontrolled hypertension (systolic blood pressure [SBP]> 150 or diastolic blood pressure [DBP]> 90 mmHg)

6. Uncontrolled seizures

7. Class III or IV heart failure by New York Heart Association (NYHA) classification

8. Has oxygen-dependent chronic disease

9. Active psychiatric disorder (schizophrenia, major depressive disorder, bipolar disorder etc.). Treated depression with ongoing antidepressant medication is not an exclusion

10. History of abdominal fistula or gastrointestinal perforation within 6 months prior to start of study drug

11. History of serious gastrointestinal haemorrhage within 6 months prior to start of study drug

12. History of severe arterial thromboembolic event within 12 months of start of study drug

13. Serious grade 4 venous thromboembolic event including pulmonary embolism

14. History of hypertensive crisis or hypertensive encephalopathy

15. History of posterior reversible encephalopathy syndrome

16. Planned surgery within 4 weeks post last dose

17. Moderate to severe proteinuria

18. Requiring therapeutic anticoagulation with warfarin at baseline

19. Not recovered below National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade 1 or baseline from AEs due to previous therapy

20. Treatment with systemic chemotherapy, hormonal therapy, immunotherapy or biologic therapy within 2 weeks prior to the baseline visit

21. Has received prior radiotherapy within 2 weeks of start of study treatment.

22. Undergone major surgery requiring general anaesthesia or a respiratory assistance device within 4 weeks prior to the baseline visit

23. Treated with other investigational drugs within 4 weeks prior to the baseline visit for this study

24. Female who is pregnant* or lactating and of childbearing potential who does not agree to a reliable and adequate method of contraception

25. A known history of severe drug hypersensitivity or hypersensitivity to a therapy similar to the study drugs

26. Unable to participate in the trial according to the investigator's decision.

27. Previous therapy with vascular endothelial growth factor (VEGF)-targeted agents including (but not limited to) bevacizumab

28. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher irAE

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

PharmAbcine

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Liverpool Hospital

Liverpool, New South Wales, Australia

Hollywood Private Hospital

Nedlands, Western Australia, Australia

Countries

Australia

Other Identifiers

PMC_TTAC-0001_05

Identifier Type: -

Identifier Source: org_study_id